TP53 and breast cancer: An experiment using 16 distinct genetically engineered mouse models of BC found that the loss of TP53 in cancer cells induced the secretion of WNT ligand, which in turn stimulated the increase in IL-1β produced by tumor-associated macrophages, and further drove systemic inflammation and ultimately promoted the progression of metastasis (Wellenstein et al., 2019).